A61K31/59

Dietary supplement containing phospholipid-DHA derived from eggs
09744182 · 2017-08-29 · ·

Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B.sub.6, vitamin B.sub.12, Vitamin E, Vitamin C, iodine, iron, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.

Dietary supplement containing phospholipid-DHA derived from eggs
09744182 · 2017-08-29 · ·

Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B.sub.6, vitamin B.sub.12, Vitamin E, Vitamin C, iodine, iron, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.

Flavored Water Composition For Pets
20170239179 · 2017-08-24 ·

A flavored water composition for pets is disclosed. The disclosed flavored water composition for pets includes water and an oil-based nutrient.

Flavored Water Composition For Pets
20170239179 · 2017-08-24 ·

A flavored water composition for pets is disclosed. The disclosed flavored water composition for pets includes water and an oil-based nutrient.

CANCER DIAGNOSIS AND THERAPY

The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

TOPICAL CYCLOSPORINE FOR TREATING PSORIASIS AND OTHER AILMENTS

Disclosed herein is a transdermal delivery formulation for transdermal delivery of cyclosporine with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject. The formulation overcomes the limitations of oral administration. Specifically, embodiments include a formulation and method of delivering cyclosporine systemically into the skin to treat psoriasis or other ailments.

TOPICAL CYCLOSPORINE FOR TREATING PSORIASIS AND OTHER AILMENTS

Disclosed herein is a transdermal delivery formulation for transdermal delivery of cyclosporine with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject. The formulation overcomes the limitations of oral administration. Specifically, embodiments include a formulation and method of delivering cyclosporine systemically into the skin to treat psoriasis or other ailments.

Nutritional composition and method for improving heart failure

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

Nutritional composition and method for improving heart failure

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

Nutritional composition and method for improving heart failure

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.